307 BISEBROMOAMIDE, AS A NOVEL MOLECULAR TARGET DRUG INHIBITING PHOSPHORYLATION OF BOTH EXTRACELLULAR SIGNAL-REGULATED KINASE AND AKT IN RENAL CELL CARCINOMA

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Kenjiro Suzuki ◽  
Ryuichi Mizuno ◽  
Kiyotake Suenaga ◽  
Takeo Kosaka ◽  
Nobuyuki Tanaka ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Target ◽  
Extracellular Signal Regulated Kinase ◽  
Target Drug ◽  
Extracellular Signal ◽  
Molecular Target Drug

scholarly journals Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma

2020 ◽  
Vol 3 (3) ◽  
pp. 360-364 ◽  
Author(s):  
Christian R. Hoerner ◽  
Rustin Massoudi ◽  
Thomas J. Metzner ◽  
Laurel Stell ◽  
Jennifer J. O’Rourke ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Activity ◽  
Extracellular Signal Regulated Kinase ◽  
Extracellular Signal

scholarly journals Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2875
Author(s):  
Yoshiyuki Matsui
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

In patients with renal cell carcinoma, brain metastasis is generally one of the poor prognostic factors. However, the recent introduction of molecular target therapy and immune checkpoint inhibitor has remarkably advanced the systemic treatment of metastatic renal cell carcinoma and prolonged the patients’ survival. The pivotal clinical trials of those agents usually excluded patients with brain metastasis. The incidence of brain metastasis has been increasing in the actual clinical setting because of longer control of extra-cranial disease. Brain metastasis subgroup data from the prospective and retrospective series have been gradually accumulated about the risk classification of brain metastasis and the efficacy and safety of those new agents for brain metastasis. While the local treatment against brain metastasis includes neurosurgery, stereotactic radiosurgery, and conventional whole brain radiation therapy, the technology of stereotactic radiosurgery has been especially advanced, and the combination with systemic therapy such as molecular target therapy and immune checkpoint inhibitor is considered promising. This review summarizes recent progression of multimodality treatment of brain metastasis of renal cell carcinoma from literature data and explores the future direction of the treatment.

Abstract LB-111: Neuronal Pentraxin 2: a novel tumor-specific molecular target that mediates clear cell renal cell carcinoma malignancy

2014 ◽  
Author(s):  
Christina A. von Roemeling ◽  
Derek C. Radisky ◽  
Laura A. Marlow ◽  
Simon J. Cooper ◽  
Stefan K. Grebe ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Molecular Target ◽  
Cell Renal Cell Carcinoma ◽  
Neuronal Pentraxin

Association between diabetes mellitus and the survival of sunitinib-treated patients with metastatic renal cell carcinoma.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 546-546
Author(s):  
Takahito Suyama ◽  
Ayumi Fujimoto ◽  
Manato Kanesaka ◽  
Kyokushin Hou ◽  
Kazuhiro Araki ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Medical Center ◽  
Rank Test ◽  
Diabetic Patients ◽  
Cancer Specific Survival ◽  
Sunitinib Treatment ◽  
Target Drug

546 Background: Diabetes mellitus is one of the major risk factor for renal cell carcinoma (RCC) development. Although, in various cancers, the relationship between diabetes mellitus and worse prognosis is pointed out, the association between RCC prognosis and diabetes mellitus is under discussion. We sought to determine the association between diabetes mellitus with outcome of sunitinib treatment in metastatic RCC (mRCC) patients. Methods: A retrospective study of sunitinib-treated mRCC patients was performed. 69 patients who had been treated with sunitinib in Japanese two institutions (Teikyo University Chiba Medical Center and Chiba University) were entered. Kaplan-Meier and the log-rank test were performed to investigate the association between the pretreatment status of diabetes mellitus and the outcome of the patients who received the treatment with sunitinib. Results: Between 2008 and 2015, 69 mRCC patients were treated with sunitinib. 53 (76.8%) patients received sunitinib treatment as the first line molecular target drug. 15 (21.7%) patients were diagnosed as diabetes mellitus at the time of sunitinib treatment. Median time to treatment failure (TTF) was 7.1 months, cancer specific survival (CSS) was 33.9 months for all patients. With regard to TTF, there was no difference between diabetic and non-diabetic patients, 9 months for diabetic patients and 7.1 months for non-diabetic patients respectively (P = 0.3271). CCS was significantly shorter for diabetic patients, 11 months for diabetic patients and 39.4 months for non-diabetic patients respectively (P = 0.0469). When focusing on HbA1c, CSS was significant longer for the patients with HbA1c under 6.5% than the patients with HbA1c was 6.5 or more, median CSS was 44.5 months and 11.3 months, respectively (P = 0.0055). Conclusions: Diabetes mellitus did not influence the TTF of sunitinib treatment for mRCC patients. Diabetes mellitus may negatively affect the CSS of sunitinib-treated mRCC. Clinicians should consider controlling patient’s HbA1c status at the initiation of sunitinib treatment for mRCC.

scholarly journals Nodal activates smad and extracellular signal-regulated kinases 1/2 pathways promoting renal cell carcinoma proliferation

2012 ◽  
Vol 12 (1) ◽  
pp. 587-594 ◽  
Author(s):  
ZHIWEI ZHANG ◽  
TAO JIANG ◽  
QUANLIN LI ◽  
JIANBO WANG ◽  
DEYONG YANG ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Extracellular Signal
Sign in / Sign up

Export Citation Format

Share Document